328 related articles for article (PubMed ID: 29512827)
1. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.
Mösges R; Bachert C; Panzner P; Calderon MA; Haazen L; Pirotton S; Wathelet N; Durham SR; Bonny MA; Legon T; von Frenckell R; Pfaar O; Shamji MH
Allergy; 2018 Sep; 73(9):1842-1850. PubMed ID: 29512827
[TBL] [Abstract][Full Text] [Related]
2. Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial.
Sharif H; Singh I; Kouser L; Mösges R; Bonny MA; Karamani A; Parkin RV; Bovy N; Kishore U; Robb A; Katotomichelakis M; Holtappels G; Derycke L; Corazza F; von Frenckell R; Wathelet N; Duchateau J; Legon T; Pirotton S; Durham SR; Bachert C; Shamji MH
J Allergy Clin Immunol; 2019 Sep; 144(3):738-749. PubMed ID: 30844425
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.
Mösges R; Kasche EM; Raskopf E; Singh J; Sohlich L; Astvatsatourov A; Shah-Hosseini K; Pirotton S; Haazen L; Durham SR; Legon T; Zadoyan G; Shamji MH
Allergy; 2018 Apr; 73(4):896-904. PubMed ID: 29150857
[TBL] [Abstract][Full Text] [Related]
4. Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients.
Mösges R; Koch AF; Raskopf E; Singh J; Shah-Hosseini K; Astvatsatourov A; Hauswald B; Yarin Y; Corazza F; Haazen L; Pirotton S; Allekotte S; Zadoyan G; Legon T; Durham SR; Shamji MH
Allergy; 2018 Jun; 73(6):1254-1262. PubMed ID: 29322510
[TBL] [Abstract][Full Text] [Related]
5. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
6. Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial.
Sola Martínez FJ; Barranco Jiménez RM; Martín García C; Senent Sánchez C; Blanco Guerra C; Fernández-Rivas M; Vega Castro A; Dávila González I; Carbonell Martínez A; Panizo Bravo C; Gómez Torrijos E; Rodríguez Gil D; Palacios Peláez R
Clin Exp Allergy; 2020 Dec; 50(12):1352-1361. PubMed ID: 32946612
[TBL] [Abstract][Full Text] [Related]
7. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
8. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
[TBL] [Abstract][Full Text] [Related]
10. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
11. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
12. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
[TBL] [Abstract][Full Text] [Related]
13. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial.
Caffarelli C; Sensi LG; Marcucci F; Cavagni G
Allergy; 2000 Dec; 55(12):1142-7. PubMed ID: 11117271
[TBL] [Abstract][Full Text] [Related]
14. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
15. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
[TBL] [Abstract][Full Text] [Related]
16. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.
Ellis AK; Frankish CW; O'Hehir RE; Armstrong K; Steacy L; Larché M; Hafner RP
J Allergy Clin Immunol; 2017 Aug; 140(2):486-496. PubMed ID: 28236469
[TBL] [Abstract][Full Text] [Related]
17. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
Skaarup SH; Schmid JM; Skjold T; Graumann O; Hoffmann HJ
J Allergy Clin Immunol; 2021 Mar; 147(3):1011-1019. PubMed ID: 32679209
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial.
Pfaar O; Klimek L
Ann Allergy Asthma Immunol; 2008 Mar; 100(3):256-63. PubMed ID: 18426146
[TBL] [Abstract][Full Text] [Related]
20. Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial.
Shamji MH; Ceuppens J; Bachert C; Hellings P; Placier G; Thirion G; Bovy N; Durham SR; Duchateau J; Legon T; Pirotton S
J Allergy Clin Immunol; 2018 Jan; 141(1):448-451. PubMed ID: 29030102
[No Abstract] [Full Text] [Related]
[Next] [New Search]